Inovio Pharmaceuticals has reported positive results from a Phase I study of VGX-3100, a DNA vaccine that achieved long-term durability of immune responses for treating cervical dysplasia and cancer caused by human papillomavirus.

The study involved 18 women with moderate or severe cervical intraepithelial neoplasia; 91% of evaluated patients displayed strong and persistent memory T-cell responses at month nine.

The generation of T-cell responses indicate the disappearance of cancerous cells from the body.

Inovio Pharmaceuticals president and CEO J Joseph Kim said that, based on the data obtained in the study, the company plans to evaluate the efficacy of VGX-3100 delivered using a Cellectra electroporation device in a randomised, placebo-controlled and double-blind Phase II trial.